enhancing benefit with durvalumab in nsclc after the pacific trial
Published 4 years ago • 294 plays • Length 1:45Download video MP4
Download video MP3
Similar videos
-
6:22
refining which patients benefit from consolidation durvalumab for stage iii unresectable nsclc
-
5:28
durvalumab consolidation in nsclc: the pacific trial
-
4:43
treating for stage iii nsclc after progression on durvalumab
-
25:26
locally advanced nsclc: combination therapy with targeted and immunotherapy agents
-
1:07
pacific trial updates: durvalumab after chemotherapy in nsclc
-
3:39
results from the pacific study: durvalumab with chemoradiation for the treatment of nsclc
-
1:08
dr. bazhenova on the pacific trial with durvalumab in nsclc
-
4:00
cancer immunotherapy - pd-1 and pd-l1
-
1:39
durvalumab mode of action
-
39:06
unleashing the potential of perioperative immunotherapy in resectable nsclc
-
2:52
examining recent pacific trial updates for durvalumab in locally advanced nsclc
-
2:10
dr. langer on the benefit of durvalumab in stage iii nsclc
-
4:16
nsclc management before and after the pacific trial
-
3:22
locally advanced nsclc: durvalumab and the pacific trial
-
5:13
effectively managing treatment with durvalumab
-
4:46
5-year survival outcomes from the pacific trial
-
6:07
pacific trial: durvalumab following chemotherapy for stage iii nsclc
-
2:14
pacific-6: durvalumab after chemoradiotherapy in unresectable stage iii nsclc | crsf
-
6:50
implications for using durvalumab in stage 3 nsclc
-
1:29
how can durvalumab be used in nsclc?
-
1:54
dr. fujioka on remaining questions after the pacific trial in nsclc
-
1:44
post-hoc subgroup analysis from pacific: durvalumab after crt in unresectable stage iii egfrm nsclc